Previous 10 | Next 10 |
The following slide deck was published by Cumberland Pharmaceuticals Inc. in conjunction with their 2022 Q1 earnings call. For further details see: Cumberland Pharmaceuticals Inc. 2022 Q1 - Results - Earnings Call Presentation
Cumberland Pharmaceuticals press release (NASDAQ:CPIX): Q1 Non-GAAP EPS of $0.03. Revenue of $11.2M (+6.3% Y/Y). Shares +1.95% AH. For further details see: Cumberland Pharmaceuticals Non-GAAP EPS of $0.03, revenue of $11.2M
Cumberland Pharmaceuticals Reports 6% Revenue Growth PR Newswire The Nashville -based specialty pharmaceutical company issues first quarter 2022 financial results and a company update NASHVILLE, Tenn. , May 10, 2022 /PRNewswire/ -- Cumbe...
Cumberland Pharmaceuticals Announces Key Co-Promotion Agreement with Verity Pharmaceuticals to Expand Support for Sancuso® PR Newswire Verity Pharmaceuticals will feature Sancuso across the U.S. through its established oncology commercial organization and cust...
CUMBERLAND PHARMACEUTICALS TO ANNOUNCE FIRST QUARTER 2022 FINANCIAL RESULTS PR Newswire NASHVILLE, Tenn. , May 3, 2022 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceuticals company, announced today that it will re...
Shares of Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) traded at a new 52-week high today of $7.95. So far today approximately 31.5 million shares have been exchanged, as compared to an average 30-day volume of 58,000 shares. Cumberland Pharmaceuticals Inc is a specialty pharmaceutical ...
Cumberland Pharmaceuticals (CPIX +15.0%) and Saudi Arabia's Tabuk Pharmaceutical Manufacturing launched the Nashville, Tenn.-based company's antibiotic Vibativ (telavancin) injection in the Middle East. Vibativ, a once-daily injectable, is approved in the U.S. fo...
TABUK AND CUMBERLAND PARTNER TO BRING INNOVATIVE ANTIBIOTIC WITH LIFE-SAVING POTENTIAL TO MIDDLE EAST PR Newswire Vibativ ® treats patients with multidrug-resistant infections NASHVILLE, Tenn. and RIYADH, Saudi Arabia , March 31, 2022 /PR...
Cumberland Pharmaceuticals Inc. (CPIX) Q4 2021 Earnings Conference Call March 8, 2022, 4:30 PM ET Company Participants Molly Aggas - Account Supervisor, Dalton Agency A.J. Kazimi - Chief Executive Officer Todd Anthony - Vice President, Organizational Development John Hamm - Chief Financial Of...
Cumberland Pharmaceuticals press release (NASDAQ:CPIX): FY GAAP EPS of -$0.29 misses by $0.26. Revenue of $8.3M (-19.1% Y/Y) misses by $32.67M. For further details see: Cumberland Pharmaceuticals GAAP EPS of -$0.29 misses by $0.26, revenue of $8.3M misses by $32.67M
News, Short Squeeze, Breakout and More Instantly...
Cumberland Pharmaceuticals Inc. Company Name:
CPIX Stock Symbol:
NASDAQ Market:
Cumberland Pharmaceuticals Inc. Website:
Cumberland Pharmaceuticals Reports First Quarter 2024 Financial Results & Company Update Cumberland Pharmaceuticals Reports First Quarter 2024 Financial Results & Company Update PR Newswire NASHVILLE, TENN . , May 7, 2024 /PRNewswire/ -- Cumberland Ph...
Aterian Inc. (ATER) is expected to report for Q1 2024 Dorman Products Inc. (DORM) is expected to report $0.82 for Q1 2024 Hillman Solutions Corp. (HLMN) is expected to report $0.08 for Q1 2024 Wake Forest Bancshares, Inc. (WAKE) is expected to report for quarter end 2024-03-31 Inn...
CUMBERLAND PHARMACEUTICALS TO ANNOUNCE FIRST QUARTER 2024 FINANCIAL RESULTS PR Newswire NASHVILLE, Tenn. , April 30, 2024 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, announced today that it will release ...